flufenamic acid has been researched along with Epilepsy, Temporal Lobe in 1 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 5.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 1.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hernández-Martín, N | 1 |
| Gomez, F | 1 |
| Silván, Á | 1 |
| Rosa, RF | 1 |
| Delgado, M | 1 |
| Bascuñana, P | 1 |
| Pozo, MÁ | 1 |
| García-García, L | 1 |
1 other study available for flufenamic acid and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Epilepsy; Epilepsy, Temporal Lobe; Flufen | 2023 |